I provide independent and original analysis, pricing metrics and recommendations for the stem, cell, gene and regenerative therapy equities.

Sangamo Therapeutics (SGMO) proposes $72.5 M offering

June 20, 2017

SGMO closes UP +$0.25 to $8.20 and promptly dives -$0.70 or -8.54% to $7.50 ​SGMO prices 10 M shares at $7.25  

Fibrocell Science (FCSC) gets “Rare Pediatric Disease Designation” from FDA

June 12, 2017

FCSC is up +$0.23 or +9.27% in the pre-market, it's a BUY with an exit defined in short timing ... news has a life cycle in this market  

Roll Call

The process of calling out our grading of covered companies to rank and review the facts in evidence together with analysis, opinion and objective recommendation.